Molecular Formula | C22H31BrN6OS |
Molar Mass | 507.5 |
Melting Point | >211°C (dec.) |
Solubility | Methanol (Slightly) |
Appearance | Solid |
Color | White to Light Beige |
Storage Condition | Refrigerator |
In vitro study | After long-term teneligliptin treatment of HUVECs (concentration range 0.1-3 mol/L),teneligliptin did not reduce its cell viability, but reduced the HG-stress markers of HUVEC under hyperglycemia, increased gene expression of heme oxygenase 1(HMOX1). Long-term treatment can also improve the proliferation ability of HUVEC cells and the endoplasmic reticulum function of HUVEC cells in high glucose state. Teneligliptin has antioxidant properties in HUVECs species with normal glucose concentrations, reducing ROS levels and initiating a transcriptional cascade of antioxidant genes. |
In vivo study | Teneligliptin has the effect of reducing weight gain, fat accumulation, reducing serum insulin and triglyceride levels in postmenopausal obese mice model. It also improved glucose intolerance without affecting insulin sensitivity. Teneligliptin attenuates chronic inflammation of perigonadal fat and hepatic steatosis, enhancing its locomotor activity and energy expenditure at night in postmenopausal obese mice. Teneligliptin reduces hepatic adipogenesis by activating AMPK and down-regulating the expression of adipogenesis-related genes. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.59 ml | 7.951 ml | 15.902 ml |
5 mM | 0.318 ml | 1.59 ml | 3.18 ml |
10 mM | 0.159 ml | 0.795 ml | 1.59 ml |
5 mM | 0.032 ml | 0.159 ml | 0.318 ml |